AVROBIO, Inc. (AVRO): Price and Financial Metrics
GET POWR RATINGS... FREE!
AVRO Stock Price Chart Interactive Chart >
AVRO Price/Volume Stats
| Current price | $0.84 | 52-week high | $11.00 |
| Prev. close | $0.79 | 52-week low | $0.74 |
| Day low | $0.75 | Volume | 447,200 |
| Day high | $1.00 | Avg. volume | 691,824 |
| 50-day MA | $1.13 | Dividend yield | N/A |
| 200-day MA | $3.41 | Market Cap | 36.69M |
AVROBIO, Inc. (AVRO) Company Bio
AVROBIO, Inc., a clinical stage gene therapy company, focuses on developing potentially curative ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose. It lead product candidate in AVR-RD-01, which is in Phase 1 clinical trial for the treatment of Fabry disease. The company is also developing AVR-RD-02 for the treatment of Gaucher disease; AVR-RD-03 for the treatment of Pompe disease; and AVR-RD-04 for the treatment of cystinosis. The company was founded in 2015 and is based in Cambridge, Massachusetts.
Latest AVRO News From Around the Web
Below are the latest news stories about AVROBIO Inc that investors may wish to consider to help them evaluate AVRO as an investment opportunity.
2 Net Current Asset Value Stocks to ConsiderShort-term investors could be interested in these businesses |
AVROBIO (AVRO) Presents At AVROBIO WORLD Symposium 2022 CystinosisNo summary available. |
Needham Thinks Avrobio’s Stock is Going to RecoverIn a report released today, Gil Blum from Needham maintained a Buy rating on Avrobio (AVRO – Research Report), with a price target of $8.00. The company's shares closed last Wednesday at $1.65, close to its 52-week low of $1.62. According to TipRanks.com, Blum is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -35.1% and a 13.0% success rate. Blum covers the Healthcare sector, focusing on stocks such as Mereo Biopharma Group Plc, Rocket Pharmaceuticals, and Aeglea Biotherapeutics. Avrobio has an analyst consensus of Moderate Buy, with a price target consensus of $5.83, representing a 216.8% upside. |
Mizuho Securities Sticks to Their Buy Rating for Avrobio (AVRO)In a report released today, Uy Ear from Mizuho Securities maintained a Buy rating on Avrobio (AVRO – Research Report), with a price target of $6.00. The company's shares closed last Wednesday at $1.65. According to TipRanks.com, Ear is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -14.9% and a 27.3% success rate. Ear covers the Healthcare sector, focusing on stocks such as Arcutis Biotherapeutics, Sarepta Therapeutics, and uniQure. Avrobio has an analyst consensus of Moderate Buy, with a price target consensus of $5.83. |
After Fabry Trial Setback, Avrobio Hopes Rebound With Lysosomal Storage Disorder DataAvrobio Inc''s (NASDAQ: AVRO ) gene therapy for a rare lysosomal storage disorder showed potential durability in the first three patients more than one year after infusion. The data comes from a Phase 1/2 trial testing the safety and efficacy of AVR-RD-04 for cystinosis who had previously been given cysteamine, which is a standard treatment that reduces the buildup of cystine crystals in … Full story available on Benzinga.com |
AVRO Price Returns
| 1-mo | -19.23% |
| 3-mo | -39.13% |
| 6-mo | N/A |
| 1-year | -90.40% |
| 3-year | -94.61% |
| 5-year | N/A |
| YTD | -78.18% |
| 2021 | -72.38% |
| 2020 | -30.75% |
| 2019 | 20.90% |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...